Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00207025 |
The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.
Condition | Intervention | Phase |
---|---|---|
Tumors |
Drug: BMS-275183 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Michigan | |
Local Institution | |
Detroit, Michigan, United States | |
United States, Pennsylvania | |
Local Institution | |
Pittsburgh, Pennsylvania, United States | |
Belgium | |
Local Institution | |
Brussels, Belgium |
Study ID Numbers: | CA165-012 |
Study First Received: | September 12, 2005 |
Last Updated: | July 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00207025 |
Health Authority: | United States: Food and Drug Administration |
Patients with advanced solid tumors |